All In Biotech

Drug Trial Radar · NCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

327

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Feb 15, 2029

Study completion Feb 15, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away

Conditions

  • Small Cell Lung Cancer

Interventions

  • GocatamigBiological

    IV infusion

  • Ifinatamab Deruxtecan (I-DXd)Biological

    IV infusion

  • DurvalumabBiological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 44 months
  2. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 3 weeks
  3. Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 44 months
  4. Part 1: Objective Response Rate (ORR)Time frame: Up to approximately 44 months

Locations

48 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus ( Site 1110)

    Aurora, Colorado · Recruiting

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)

    Miami, Florida · Recruiting

  • University of Chicago ( Site 1108)

    Chicago, Illinois · Recruiting

  • Dana Farber Cancer Institute ( Site 1105)

    Boston, Massachusetts · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)

    Hackensack, New Jersey · Recruiting

  • Roswell Park Cancer Institute ( Site 1107)

    Buffalo, New York · Recruiting

  • Providence Portland Medical Center ( Site 1101)

    Portland, Oregon · Recruiting

  • Sarah Cannon Research Institute ( Site 7001)

    Nashville, Tennessee · Recruiting

  • Medical College of Wisconsin ( Site 1112)

    Milwaukee, Wisconsin · Recruiting

  • Hospital Universitario Austral ( Site 2204)

    Pilar, Buenos Aires, Argentina · Recruiting

  • Sanatorio Parque ( Site 2203)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Princess Alexandra Hospital ( Site 5300)

    Woolloongabba, Queensland, Australia · Recruiting

  • Monash Health ( Site 5301)

    Clayton, Victoria, Australia · Recruiting

  • FALP ( Site 2100)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 2102)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 2101)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer Hospital ( Site 5401)

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital ( Site 5413)

    Fuzhou, Fujian, China · Recruiting

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403)

    Nanjing, Jiangsu, China · Recruiting

  • Shanghai Chest Hospital ( Site 5400)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital ( Site 5405)

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University ( Site 5416)

    Chengdu, Sichuan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University ( Site 5404)

    Hangzhou, Zhejiang, China · Recruiting

  • Rambam Health Care Campus ( Site 3202)

    Haifa, Israel · Active not recruiting

  • Shaare Zedek Medical Center ( Site 3200)

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center ( Site 3203)

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center ( Site 3201)

    Ramat Gan, Israel · Recruiting

  • Aichi Cancer Center ( Site 5000)

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East ( Site 5001)

    Kashiwa, Chiba, Japan · Recruiting

  • Kansai Medical University Hospital ( Site 5004)

    Hirakata, Osaka, Japan · Recruiting

  • Cancer Institute Hospital of JFCR ( Site 5002)

    Koto, Tokyo, Japan · Recruiting

  • Seoul National University Hospital ( Site 5100)

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 5102)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 5101)

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall d'Hebron ( Site 3311)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315)

    Madrid, Spain · Recruiting

  • Hospital Universitario HM Sanchinarro ( Site 3313)

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen de la Victoria ( Site 3312)

    Málaga, Spain · Recruiting

  • HOSPITAL CLÍNIC DE BARCELONA ( Site 3310)

    Eixample, Barcelona, Spain · Recruiting

  • Institut Català d'Oncologia - L'Hospitalet ( Site 3317)

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.